Sign in to use this feature.

Years

Between: -

Subjects

remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline

Journals

Article Types

Countries / Regions

Search Results (59)

Search Parameters:
Keywords = affordable care act

Order results
Result details
Results per page
Select all
Export citation of selected articles as:
18 pages, 1420 KiB  
Review
Unequal Gains? A Literature Review on the Affordable Care Act’s Effects on Healthcare Utilization Across Racial and Ethnic Groups
by Ahmad Reshad Osmani
Int. J. Environ. Res. Public Health 2025, 22(7), 1059; https://doi.org/10.3390/ijerph22071059 - 2 Jul 2025
Viewed by 634
Abstract
The Affordable Care Act (ACA), implemented in 2010, aimed to expand healthcare access, reduce costs, and address long-standing disparities in the U.S. healthcare system, particularly among racial and ethnic minorities. This paper reviews the ACA’s impact on healthcare utilization for these populations, with [...] Read more.
The Affordable Care Act (ACA), implemented in 2010, aimed to expand healthcare access, reduce costs, and address long-standing disparities in the U.S. healthcare system, particularly among racial and ethnic minorities. This paper reviews the ACA’s impact on healthcare utilization for these populations, with a focus on insurance coverage, preventive services, and health outcomes. While Medicaid expansion significantly reduced uninsured rates and increased access to care in states that adopted the expansion, millions of low-income individuals, many of whom are racial and ethnic minorities, remain uninsured in non-expansion states. The elimination of cost-sharing for preventive services under the ACA contributed to increased utilization of cancer screenings, vaccinations, and other preventive measures among minority groups. However, challenges persist, including affordability barriers, geographic disparities, and cultural and linguistic obstacles. This review also highlights the ongoing need for policy interventions, such as nationwide Medicaid expansion, and future research on the long-term effects of the ACA on health outcomes for minority populations. Full article
(This article belongs to the Section Global Health)
Show Figures

Figure 1

41 pages, 5838 KiB  
Review
Reforming Food, Drug, and Nutraceutical Regulations to Improve Public Health and Reduce Healthcare Costs
by Sunil J. Wimalawansa
Foods 2025, 14(13), 2328; https://doi.org/10.3390/foods14132328 - 30 Jun 2025
Viewed by 1484
Abstract
Neglecting preventive healthcare policies has contributed to the global surge in chronic diseases, increased hospitalizations, declining quality of care, and escalating costs. Non-communicable diseases (NCDs)—notably cardiovascular conditions, diabetes, and cancer—consume over 80% of healthcare expenditure and account for more than 60% of global [...] Read more.
Neglecting preventive healthcare policies has contributed to the global surge in chronic diseases, increased hospitalizations, declining quality of care, and escalating costs. Non-communicable diseases (NCDs)—notably cardiovascular conditions, diabetes, and cancer—consume over 80% of healthcare expenditure and account for more than 60% of global deaths, which are projected to exceed 75% by 2030. Poor diets, sedentary lifestyles, regulatory loopholes, and underfunded public health initiatives are driving this crisis. Compounding the issue are flawed policies, congressional lobbying, and conflicts of interest that prioritize costly, hospital-based, symptom-driven care over identifying and treating to eliminate root causes and disease prevention. Regulatory agencies are failing to deliver their intended functions. For instance, the U.S. Food and Drug Administration’s (FDA) broad oversight across drugs, devices, food, and supplements has resulted in inefficiencies, reduced transparency, and public safety risks. This broad mandate has allowed the release of unsafe drugs, food additives, and supplements, contributing to the rising childhood diseases, the burden of chronic illness, and over-medicalization. The author proposes separating oversight responsibilities: transferring authority over food, supplements, and OTC products to a new Food and Nutraceutical Agency (FNA), allowing the FDA to be restructured as the Drug and Device Agency (DDA), to refocus on pharmaceuticals and medical devices. While complete reform requires Congressional action, interim policy shifts are urgently needed to improve public health. Broader structural changes—including overhauling the Affordable Care Act, eliminating waste and fraud, redesigning regulatory and insurance systems, and eliminating intermediaries are essential to reducing costs, improving care, and transforming national and global health outcomes. The information provided herein can serve as a White Paper to help reform health agencies and healthcare systems for greater efficiency and lower costs in the USA and globally. Full article
Show Figures

Figure 1

16 pages, 922 KiB  
Review
Health Policy and Screening for Colorectal Cancer in the United States
by Maryam R. Hussain, Faisal S. Ali, Scott A. Larson and Soham Al Snih
Cancers 2025, 17(12), 2003; https://doi.org/10.3390/cancers17122003 - 16 Jun 2025
Viewed by 1169
Abstract
The landscape for the screening of colorectal cancer (CRC) has witnessed multiple triumphs over the past decades from policy-level interventions. In the United States (US), the most prominent intervention of this nature is the Patient Protection and Affordable Care Act (ACA), enacted more [...] Read more.
The landscape for the screening of colorectal cancer (CRC) has witnessed multiple triumphs over the past decades from policy-level interventions. In the United States (US), the most prominent intervention of this nature is the Patient Protection and Affordable Care Act (ACA), enacted more than a decade ago. Since its enactment, the ACA has seen multiple legal challenges, and its impact on CRC screening has been relatively well studied. However, a consolidated, concise analysis of the data on this subject is lacking. Herein, we evaluate the impact of the ACA on CRC screening through the lens of a policy analysis, highlighting its strengths and shortcomings, and suggest policy-level interventions to address these shortcomings and improve CRC screening adoption. Full article
(This article belongs to the Section Cancer Causes, Screening and Diagnosis)
Show Figures

Figure 1

59 pages, 1891 KiB  
Review
Advances in Biologic Therapies for Allergic Diseases: Current Trends, Emerging Agents, and Future Perspectives
by Ewa Alska, Dariusz Łaszczych, Katarzyna Napiórkowska-Baran, Bartłomiej Szymczak, Alicja Rajewska, Aleksandra Ewa Rubisz, Paulina Romaniuk, Katarzyna Wrzesień, Natalia Mućka and Zbigniew Bartuzi
J. Clin. Med. 2025, 14(4), 1079; https://doi.org/10.3390/jcm14041079 - 8 Feb 2025
Cited by 2 | Viewed by 3676
Abstract
Biologic therapies have revolutionized the treatment of severe allergic diseases, including asthma, atopic dermatitis (AD), chronic spontaneous urticaria (CSU), chronic rhinosinusitis with nasal polyps (CRSwNP), eosinophilic gastrointestinal diseases (EGIDs), and allergic rhinitis (AR). These molecularly targeted agents provide significant benefits for patients unresponsive [...] Read more.
Biologic therapies have revolutionized the treatment of severe allergic diseases, including asthma, atopic dermatitis (AD), chronic spontaneous urticaria (CSU), chronic rhinosinusitis with nasal polyps (CRSwNP), eosinophilic gastrointestinal diseases (EGIDs), and allergic rhinitis (AR). These molecularly targeted agents provide significant benefits for patients unresponsive to conventional treatments by addressing underlying immune mechanisms, particularly type 2 inflammation driven by cytokines such as IL-4, IL-5, and IL-13. Recent advancements include biologics targeting alarmins like thymic stromal lymphopoietin (TSLP) and IL-33, which may address both type 2 and non-type 2 inflammation, broadening their therapeutic scope. Despite their effectiveness, biologics remain expensive, posing socioeconomic challenges, and there are concerns regarding long-term safety and inter-individual variability in responses. Promising innovations such as bispecific antibodies and ultra-long-acting agents are under investigation, alongside digital health tools like remote biomarker monitoring and AI-driven decision support systems, which aim to enhance personalized care. However, disparities in access, particularly for underserved populations, underscore the need for policy reforms and affordable biosimilars. This review synthesizes recent findings and emerging trends, highlighting the evolving role of biologics in transforming allergic disease management and offering insights into future research directions. Full article
(This article belongs to the Section Pharmacology)
Show Figures

Figure 1

18 pages, 1299 KiB  
Article
Association Between Medicaid Expansion and Insurance Status, Risk Group, Receipt, and Refusal of Treatment Among Men with Prostate Cancer
by Tej A. Patel, Bhav Jain, Edward Christopher Dee, Khushi Kohli, Sruthi Ranganathan, James Janopaul-Naylor, Brandon A. Mahal, Kosj Yamoah, Sean M. McBride, Paul L. Nguyen, Fumiko Chino, Vinayak Muralidhar, Miranda B. Lam and Neha Vapiwala
Cancers 2025, 17(3), 547; https://doi.org/10.3390/cancers17030547 - 6 Feb 2025
Viewed by 1219
Abstract
Background: Although the Patient Protection and Affordable Care Act (ACA) has been associated with increased Medicaid coverage among prostate cancer patients, the association between Medicaid expansion with risk group at diagnosis, time to treatment initiation (TTI), and the refusal of locoregional treatment [...] Read more.
Background: Although the Patient Protection and Affordable Care Act (ACA) has been associated with increased Medicaid coverage among prostate cancer patients, the association between Medicaid expansion with risk group at diagnosis, time to treatment initiation (TTI), and the refusal of locoregional treatment (LT) among patients requires further exploration. Methods: Using the National Cancer Database, we performed a retrospective cohort analysis of all patients aged 40 to 64 years diagnosed with localized prostate cancer from 2011 to 2016. Difference-in-difference (DID) analysis was used to compare changes in insurance status, risk group at diagnosis, TTI, and the refusal of LT among patients residing in Medicaid expansion versus non-expansion states. In a secondary analysis, we used DID to compare changes in the above outcomes among racial minorities versus White patients living in expansion states. Results: Of the 112,434 patients with prostate cancer in our analysis, 50,958 patients lived in Medicaid expansion states, and 61,476 patients lived in non-expansion states. In the adjusted analysis, we found that the proportion of uninsured patients (adjusted DID: −0.87%; 95% confidence interval [95% CI]: −1.28 to −0.46) and patients who refused radiation therapy (adjusted DID: −0.71%; 95% CI: −0.95 to −0.47) decreased more in expansion states compared to non-expansion states. Similarly, we observed that the racial disparity of select outcomes in expansion states narrowed, as racial minorities experienced larger absolute decreases in uninsured status and the refusal of radiation therapy (RT) regimens than White patients following ACA implementation (p < 0.01 for all). However, residence in a Medicaid expansion state was not associated with changes in risk group at diagnosis, TTI, nor the refusal of LT (p > 0.01 for all); racial disparities in TTI were also exacerbated in expansion states following ACA implementation. Conclusions: The association between Medicaid expansion and prostate cancer outcomes and disparities remains unclear. While ACA implementation was associated with increased insurance coverage and decreased refusal of RT, there was no significant association with earlier risk group at diagnosis, TTI within 180 days, or refusal of LT. Similarly, racial minorities in expansion states had larger decreases in uninsured status and the refusal of RT regimens, as well as smaller increases in intermediate-/high-risk disease at presentation than White patients following ACA implementation, but experienced no significant changes in TTI. More research is needed to understand how Medicaid expansion affects cancer outcomes and whether these effects are borne equitably among different populations. Full article
(This article belongs to the Special Issue Advances in Prostate Cancer Radiotherapy)
Show Figures

Figure 1

50 pages, 4790 KiB  
Review
Design, New Materials, and Production Challenges of Bioplastics-Based Food Packaging
by Phil Rosenow, Carmen Fernández-Ayuso, Pedro López-García and Luis Francisco Minguez-Enkovaara
Materials 2025, 18(3), 673; https://doi.org/10.3390/ma18030673 - 3 Feb 2025
Cited by 2 | Viewed by 2760
Abstract
This paper outlines the current design trends in food packaging, its main environmentally friendly material alternatives, and industrial processing technologies. In this respect, this important product has undergone several evolutions throughout history. Initially acting as a containment device, it has later evolved into [...] Read more.
This paper outlines the current design trends in food packaging, its main environmentally friendly material alternatives, and industrial processing technologies. In this respect, this important product has undergone several evolutions throughout history. Initially acting as a containment device, it has later evolved into a source of information and even a marketing platform for food companies, always with a view to extending shelf life. However, these functionalities are highly dependent on the materials used and their properties. In this respect, plastics have conquered the food packaging market due to their affordability and flexibility. Nevertheless, environmental concerns have arisen due to their impact on the environment, in addition to the introduction of stricter industry regulations and increased consumer environmental awareness. Therefore, this work found that the current design trends in food packaging are toward sustainability, reducing packaging complexity, with easier recycling, and material selection that combines both sustainability and functionality. In the case of bioplastics as a sustainable alternative, there is still room for improvement in their production, with careful consideration of their raw materials. In addition, their technical performance is generally lower, with challenges in barrier properties and processability, which could be addressed with the adoption of Industry 4.0. Full article
Show Figures

Graphical abstract

27 pages, 963 KiB  
Article
The Documentation Status Continuum and the Impact of Categories on Healthcare Stratification
by Tiffany Denise Joseph
Soc. Sci. 2025, 14(1), 41; https://doi.org/10.3390/socsci14010041 - 14 Jan 2025
Cited by 1 | Viewed by 1736
Abstract
Public discourse on immigration and social services access has been contentious in immigrant-receiving countries. Scholars have examined immigrants’ marginalization as a form of civic stratification, where boundaries based on documentation status affect immigrants’ experiences and benefits granted by the state. This scholarship lacks [...] Read more.
Public discourse on immigration and social services access has been contentious in immigrant-receiving countries. Scholars have examined immigrants’ marginalization as a form of civic stratification, where boundaries based on documentation status affect immigrants’ experiences and benefits granted by the state. This scholarship lacks a framework outlining existing documentation status categories and does not fully answer three research questions I pose in this article: (1) what is the alignment of documentation status categories relative to each other, (2) how does policy (re)configure those categories over time, and (3) how have documentation status categories shaped access to health care in the United States? This article answers those questions and argues that the documentation status continuum (DSC) framework fills these gaps. In the DSC, undocumented immigrants are at one end and citizens are at the other, with many documentation statuses in between. Public policy creates these statuses and generates stratification through allocating benefits based on one’s DSC position. Policy also shapes movement along the continuum, which shapes benefits eligibility. Using the 2006 Massachusetts Health Reform and national 2010 Affordable Care Act (ACA) Reform as policy examples and interviews conducted with 207 immigrants, healthcare professionals, and immigrant organization employees in Boston, this article demonstrates how healthcare access is stratified along the DSC between citizens and noncitizens. This has implications for various outcomes that social scientists examine amid increasing anti-immigrant sentiment in the US and beyond. Full article
(This article belongs to the Special Issue Civil Society, Migration and Citizenship)
Show Figures

Figure 1

11 pages, 222 KiB  
Article
Medicaid Expansion Increases Treatment for Patients with Colon Cancer
by John Morgan Lyons, Denise M. Danos, Lauren S. Maniscalco, Yong Yi, Omeed Moaven, Xiaocheng Wu and Quyen Chu
Cancers 2025, 17(2), 207; https://doi.org/10.3390/cancers17020207 - 10 Jan 2025
Cited by 1 | Viewed by 1038
Abstract
Introduction: Medicaid expansion (ME) has positively impacted colon cancer screening. ME’s effect on colon cancer treatment is less clear. This study analyses the effect of ME on patterns of colon cancer treatment. Methods: Patients with primary invasive colon cancer were identified using the [...] Read more.
Introduction: Medicaid expansion (ME) has positively impacted colon cancer screening. ME’s effect on colon cancer treatment is less clear. This study analyses the effect of ME on patterns of colon cancer treatment. Methods: Patients with primary invasive colon cancer were identified using the Louisiana Tumor Registry. Patients diagnosed with colon cancer prior to ME (2014–2015) were compared to those diagnosed after (2017–2018). Coordinate variables were analyzed using Fisher’s exact test. Treatment status was modeled with multivariable logistic regression and the results are reported as adjusted odds ratios. Results: The proportion of uninsured patients decreased following ME (5.5 versus 1.9, p < 0.001), with the greatest reductions among patients between 45 and 54 years old (13.5% to 3.5%, p < 0.0001), African Americans (8.9 to 2.1%, p < 0.0001), and those in high-poverty neighborhoods (7.1 to 2.1%, p < 0.0001). Following ME, all patients with Stage I-III disease were more likely to receive surgery (OR = 1.95; 95%: CI 1.21–3.14)—especially the extremely impoverished (OR = 2.39; 95% CI 1.41–4.02). Young patients with Stage IV colon cancer were more likely to receive chemotherapy (OR-1.6; 95% CI 1.03–2.4). Patients with Stage IV colon cancer were less likely to receive treatment within 30 days of diagnosis (OR = 0.7; 95% CI 0.5–0.9), but, on subset analysis, this was only observed in non-Medicaid patients. Conclusion: ME is associated with increased treatment for patients with colon cancer, and it did not appear to affect time to treatment. However, it seems to affect different subsets of the population differently. Full article
(This article belongs to the Section Cancer Epidemiology and Prevention)
12 pages, 1356 KiB  
Review
Understanding Barriers to Hepatitis C Antiviral Treatment in Low–Middle-Income Countries
by Rashmi Venkatesh, Andrew S. Huang, Kiya Gurmessa and Edbert B. Hsu
Healthcare 2025, 13(1), 43; https://doi.org/10.3390/healthcare13010043 - 30 Dec 2024
Cited by 1 | Viewed by 1651
Abstract
Background: Direct-acting antiviral agents (DAAs) have significantly reduced Hepatitis C Virus (HCV) transmission and improved health outcomes since their FDA approval in 2011. Despite these advances, over 70 million people remain untreated globally, with a disproportionately high burden in low- and middle-income [...] Read more.
Background: Direct-acting antiviral agents (DAAs) have significantly reduced Hepatitis C Virus (HCV) transmission and improved health outcomes since their FDA approval in 2011. Despite these advances, over 70 million people remain untreated globally, with a disproportionately high burden in low- and middle-income countries (LMICs). Methods: Through a structured search of open access informational sources and an informal peer-reviewed literature review, HCV treatment barriers were identified, compiled, and analyzed. Current challenges to HCV treatment were organized by themes and summarized as recommendations for LMICs. Results: Key obstacles to HCV treatment in LMICs are identified, with the underdiagnosis and undertreatment of the disease linked to inadequate funding and healthcare infrastructure for screening and testing, poor awareness among healthcare providers, and the misinformation and stigmatization of HCV disease. Discussion: Recommendations for LMICs to attenuate treatment obstacles include distributing educational media, implementing mobile clinics, and fostering international partnerships. The successful implementation of these interventions has been demonstrated in developed countries. Conclusions: To achieve the WHO’s goal of eliminating HCV as a public health threat by 2030, concerted efforts are needed by LMICs to reduce gaps in care and ensure that all patients are afforded access to testing and treatment. Full article
(This article belongs to the Special Issue Management of Chronic Health Situations)
Show Figures

Figure 1

11 pages, 757 KiB  
Article
The Impact of Medicaid Expansion on Stage at Diagnosis of Melanoma Patients: A Retrospective Study
by Ramya Muddasani, Helena T. Wu, Shwe Win, Arya Amini, Badri Modi, Ravi Salgia, Vijay Trisal, Edward W. Wang, Miguel Angel Villalona-Calero, Aaron Chan and Yan Xing
Cancers 2025, 17(1), 61; https://doi.org/10.3390/cancers17010061 - 28 Dec 2024
Cited by 4 | Viewed by 1161
Abstract
Background: This study addresses the lack of research on Medicaid expansion’s impact on melanoma staging, treatment utilization, and outcomes by evaluating its effects under the Affordable Care Act (ACA), particularly focusing on staging at diagnosis, treatment use, and 3-year mortality outcomes. The objective [...] Read more.
Background: This study addresses the lack of research on Medicaid expansion’s impact on melanoma staging, treatment utilization, and outcomes by evaluating its effects under the Affordable Care Act (ACA), particularly focusing on staging at diagnosis, treatment use, and 3-year mortality outcomes. The objective is to determine whether Medicaid expansion led to earlier melanoma diagnosis and improved survival rates among non-elderly adults (ages 40–64) by analyzing data from the National Cancer Database (NCDB). Methods: A total of 12,667 patients, aged 40–64, diagnosed with melanoma from 2010 to 2020 were identified using the NCDB. Difference-in-difference (DID) analysis was performed to analyze tumor staging at presentation between Medicaid expansion states and non-Medicaid expansion states both prior to the expansion and after the expansion. Results: Of the total patients, 2307 were from the pre-expansion time period residing in Medicaid expansion states (MES) and 1804 in non-Medicaid expansion states. In the post-expansion time period there were 5571 residing in the MES and 2985 in the non-MES. DID analysis revealed a decrease in stage IV melanoma at diagnosis (DID −0.222, p < 0.001) between MES and non-MES before and after Medicaid expansion. After expansion, in stage IV, the occurrence of primary surgery was 0.42 in non-MES and 0.44 (difference 0.02); DID analysis was not statistically significant. The use of immunotherapy in MES was significantly higher than in non-MES after expansion (p < 0.001), although DID analysis did not reveal a statistically significant difference. DID analysis showed a statistically significant decrease in 3-year mortality (DID −0.05, p = 0.001) between MES and non-MES before and after Medicaid expansion. Conclusions: This study revealed the positive impact of the ACA’s Medicaid expansion on melanoma stage at presentation, highlighting the importance of public health policies in reducing disparities in mortality rates and early-stage diagnoses. Future research should explore additional barriers to care and evaluate the long-term outcomes of Medicaid expansion to optimize cancer care for vulnerable populations. Full article
(This article belongs to the Section Cancer Survivorship and Quality of Life)
Show Figures

Figure 1

22 pages, 1047 KiB  
Article
Examining the Impacts of House Prices on Self-Rated Health of Older Adults: The Mediating Role of Subjective Well-Being
by Min Wang, Zixuan Tan, Ruying Chen and Xuefang Zhuang
Buildings 2025, 15(1), 53; https://doi.org/10.3390/buildings15010053 - 27 Dec 2024
Cited by 3 | Viewed by 899
Abstract
As the global aging trend increases, older adults are placing greater emphasis on their health. Evidence indicates that there is a complex association between house prices and older adults’ health, with their subjective well-being potentially acting as a mediator in this connection. A [...] Read more.
As the global aging trend increases, older adults are placing greater emphasis on their health. Evidence indicates that there is a complex association between house prices and older adults’ health, with their subjective well-being potentially acting as a mediator in this connection. A mediation model, utilizing data from China’s 2018 Labor Dynamics Survey, was employed to examine the impact pathway of house prices, subjective well-being, and self-rated health, while investigating the differences between young-old and old-old groups. The major findings are as follows: (1) House prices negatively affected self-rated health among the older adults. (2) The subjective well-being of older adults mediated the pathway through which house prices affected their self-rated health. (3) For old-old adults, higher house prices were more strongly linked to an increased likelihood of reporting good, very good, or excellent health. Subjective well-being was more significantly associated with reporting better health among the young-old group. Compared with the young-old population, the impact of house prices on self-rated health was stronger among the old-old, and the degree increased with increasing age. Consequently, to improve older adults’ well-being and self-rated health, effective healthy-aging policies should not only consider the influence of the real estate market, but also balance the allocation of elderly service facilities, promote affordable housing, and implement a combination of medical and nursing care from the perspective of urban planning. Full article
(This article belongs to the Special Issue Research on Health, Wellbeing and Urban Design)
Show Figures

Figure 1

18 pages, 1023 KiB  
Review
Prevalence and Modes of Transmission of Hepatitis C Virus Infection: A Historical Worldwide Review
by Tommaso Stroffolini and Giacomo Stroffolini
Viruses 2024, 16(7), 1115; https://doi.org/10.3390/v16071115 - 11 Jul 2024
Cited by 31 | Viewed by 6021
Abstract
Hepatitis C virus infection affects over 58 million individuals and is responsible for 290,000 annual deaths. The infection spread in the past via blood transfusion and iatrogenic transmission due to the use of non-sterilized glass syringes mostly in developing countries (Cameroon, Central Africa [...] Read more.
Hepatitis C virus infection affects over 58 million individuals and is responsible for 290,000 annual deaths. The infection spread in the past via blood transfusion and iatrogenic transmission due to the use of non-sterilized glass syringes mostly in developing countries (Cameroon, Central Africa Republic, Egypt) but even in Italy. High-income countries have achieved successful results in preventing certain modes of transmission, particularly in ensuring the safety of blood and blood products, and to a lesser extent, reducing iatrogenic exposure. Conversely, in low-income countries, unscreened blood transfusions and non-sterile injection practices continue to play major roles, highlighting the stark inequalities between these regions. Currently, injection drug use is a major worldwide risk factor, with a growing trend even in low- and middle-income countries (LMICs). Emerging high-risk groups include men who have sex with men (MSM), individuals exposed to tattoo practices, and newborns of HCV-infected pregnant women. The World Health Organization (WHO) has proposed direct-acting antiviral (DAA) therapy as a tool to eliminate infection by interrupting viral transmission from infected to susceptible individuals. However, the feasibility of this ambitious and overly optimistic program generates concern about the need for universal screening, diagnosis, linkage to care, and access to affordable DAA regimens. These goals are very hard to reach, especially in LMICs, due to the cost and availability of drugs, as well as the logistical complexities involved. Globally, only a small proportion of individuals infected with HCV have been tested, and an even smaller fraction of those have initiated DAA therapy. The absence of an effective vaccine is a major barrier to controlling HCV infection. Without a vaccine, the WHO project may remain merely an illusion. Full article
(This article belongs to the Special Issue Hepatitis C Virus: From Epidemiology to Treatment)
Show Figures

Figure 1

13 pages, 1089 KiB  
Review
The Role of Street Medicine and Mobile Clinics for Persons Experiencing Homelessness: A Scoping Review
by Rebekah A. Kaufman, Mahwish Mallick, Jarvis Thanex Louis, Mollie Williams and Nancy Oriol
Int. J. Environ. Res. Public Health 2024, 21(6), 760; https://doi.org/10.3390/ijerph21060760 - 12 Jun 2024
Cited by 9 | Viewed by 5460
Abstract
Introduction: An estimated 5800 to 46,500 lives are lost due to homelessness each year. Experiencing homelessness and poor health are cyclically related, with one reinforcing the other. Mobile programs, which include vehicles that travel to deliver care, and street medicine, the act of [...] Read more.
Introduction: An estimated 5800 to 46,500 lives are lost due to homelessness each year. Experiencing homelessness and poor health are cyclically related, with one reinforcing the other. Mobile programs, which include vehicles that travel to deliver care, and street medicine, the act of bringing care to spaces where PEH live, may play a role in alleviating this burden by providing trusted, affordable, and accessible care to this community. Methods: We conducted a scoping review of peer-reviewed literature on the role of mobile clinics and street medicine in providing care for PEH by searching PubMed, Embase, and Web of Science on 10 August 2023. Articles from 2013 to 2023 specific to programs in the United States were included. The protocol was developed following the PRISMA-ScR guidelines. The primary outcome was the role of mobile programs for persons experiencing homelessness. Results: A total of 15 articles were included in this review. The descriptive findings emphasized that street medicine and mobile clinics provide primary care, behavioral health, and social services. The utilization findings indicate that street medicine programs positively impact the health system through their ability to defer emergency department and hospital visits, providing financial benefits. The comparative findings between mobile programs and office-based programs indicate current successes and areas for improvement. Discussion: Mobile clinics and street medicine programs that serve PEH provide a wide range of services. While more significant structural change is needed to address healthcare costs and housing policies in the United States, mobile clinics and street medicine teams can improve healthcare access and the healthcare system. Full article
Show Figures

Figure 1

22 pages, 1799 KiB  
Review
Potential Role of Phytochemicals as Glucagon-like Peptide 1 Receptor (GLP-1R) Agonists in the Treatment of Diabetes Mellitus
by Julianah Ore Abiola, Ayoola Abidemi Oluyemi, Olajumoke Tolulope Idowu, Oluwatoyin Mary Oyinloye, Chukwudi Sunday Ubah, Olutunmise Victoria Owolabi, Oluwatobi T. Somade, Sunday Amos Onikanni, Basiru Olaitan Ajiboye, Foluso Oluwagbemiga Osunsanmi, Oyekanmi Nash, Olaposi Idowu Omotuyi and Babatunji Emmanuel Oyinloye
Pharmaceuticals 2024, 17(6), 736; https://doi.org/10.3390/ph17060736 - 5 Jun 2024
Cited by 10 | Viewed by 7795
Abstract
Currently, there is no known cure for diabetes. Different pharmaceutical therapies have been approved for the management of type 2 diabetes mellitus (T2DM), some are in clinical trials and they have been classified according to their route or mechanism of action. Insulin types, [...] Read more.
Currently, there is no known cure for diabetes. Different pharmaceutical therapies have been approved for the management of type 2 diabetes mellitus (T2DM), some are in clinical trials and they have been classified according to their route or mechanism of action. Insulin types, sulfonylureas, biguanides, alpha-glucosidase inhibitors, thiazolidinediones, meglitinides, sodium–glucose cotransporter type 2 inhibitors, and incretin-dependent therapies (glucagon-like peptide-1 receptor agonists: GLP-1R, and dipeptidyl peptidase 4 inhibitors: DPP-4). Although some of the currently available drugs are effective in the management of T2DM, the side effects resulting from prolonged use of these drugs remain a serious challenge. GLP-1R agonists are currently the preferred medications to include when oral metformin alone is insufficient to manage T2DM. Medicinal plants now play prominent roles in the management of various diseases globally because they are readily available and affordable as well as having limited and transient side effects. Recently, studies have reported the ability of phytochemicals to activate glucagon-like peptide-1 receptor (GLP-1R), acting as an agonist just like the GLP-1R agonist with beneficial effects in the management of T2DM. Consequently, we propose that careful exploration of phytochemicals for the development of novel therapeutic candidates as GLP-1R agonists will be a welcome breakthrough in the management of T2DM and the co-morbidities associated with T2DM. Full article
(This article belongs to the Special Issue Therapeutic Effects of Natural Products and Their Clinical Research)
Show Figures

Figure 1

21 pages, 4964 KiB  
Systematic Review
Systematic Review and Meta-Analysis of the Financial Impact of 30-Day Readmissions for Selected Medical Conditions: A Focus on Hospital Quality Performance
by Iwimbong Kum Ghabowen, Josue Patien Epane, Jay J. Shen, Xan Goodman, Zo Ramamonjiarivelo and Ferhat Devrim Zengul
Healthcare 2024, 12(7), 750; https://doi.org/10.3390/healthcare12070750 - 29 Mar 2024
Cited by 5 | Viewed by 4675
Abstract
Background: The Patient Protection and Affordable Care Act (ACA) established the Hospital Quality Initiative in 2010 to enhance patient safety, reduce hospital readmissions, improve quality, and minimize healthcare costs. In response, this study aims to systematically review the literature and conduct a meta-analysis [...] Read more.
Background: The Patient Protection and Affordable Care Act (ACA) established the Hospital Quality Initiative in 2010 to enhance patient safety, reduce hospital readmissions, improve quality, and minimize healthcare costs. In response, this study aims to systematically review the literature and conduct a meta-analysis to estimate the average cost of procedure-specific 30-day risk-standardized unplanned readmissions for Acute Myocardial Infarction (AMI), Heart Failure (HF), Pneumonia, Coronary Artery Bypass Graft (CABG), and Total Hip Arthroplasty and/or Total Knee Arthroplasty (THA/TKA). Methods: Eligibility Criteria: This study included English language original research papers from the USA, encompassing various study designs. Exclusion criteria comprise studies lacking empirical evidence on hospital financial performance. Information Sources: A comprehensive search using relevant keywords was conducted across databases from January 1990 to December 2019 (updated in March 2021), covering peer-reviewed articles and gray literature. Risk of Bias: Bias in the included studies was assessed considering study design, adjustment for confounding factors, and potential effect modifiers. Synthesis of Results: The review adhered to PRISMA guidelines. Employing Monte Carlo simulations, a meta-analysis was conducted with 100,000 simulated samples. Results indicated mean 30-day readmission costs: USD 16,037.08 (95% CI, USD 15,196.01–16,870.06) overall, USD 6852.97 (95% CI, USD 6684.44–7021.08) for AMI, USD 9817.42 (95% CI, USD 9575.82–10,060.43) for HF, and USD 21,346.50 (95% CI, USD 20,818.14–21,871.85) for THA/TKA. Discussion: Despite the financial challenges that hospitals face due to the ACA and the Hospital Readmissions Reduction Program, this meta-analysis contributes valuable insights into the consistent cost trends associated with 30-day readmissions. Conclusions: This systematic review and meta-analysis provide comprehensive insights into the financial implications of 30-day readmissions for specific medical conditions, enhancing our understanding of the nexus between healthcare quality and financial performance. Full article
(This article belongs to the Section Health Assessments)
Show Figures

Figure 1

Back to TopTop